Drugs / TenoMiR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04670289 | Aug 2020 → May 2021 | epicondylitis | Causeway Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06192927 | Apr 2024 → Mar 2025 | epicondylitis | Causeway Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TenoMiR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06192927 ↗ |
| Action | Restore | “has been created to restore miR29a levels back to pre-injury levels” NCT04670289 ↗ |
| Modality | Oligonucleotide (other) | “TenoMiR a chemically synthesised mimic of microRNA-29a (miR29a)” NCT04670289 ↗ |
| Route | Other | “TenoMiR intralesional injection” NCT04670289 ↗ |